240 related articles for article (PubMed ID: 26587011)
1. Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer.
Arsenic R; Treue D; Lehmann A; Hummel M; Dietel M; Denkert C; Budczies J
BMC Clin Pathol; 2015; 15():20. PubMed ID: 26587011
[TBL] [Abstract][Full Text] [Related]
2. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of
Chao TC; Tsai YF; Liu CY; Lien PJ; Lin YS; Feng CJ; Chen YJ; Lai JI; Hsu CY; Lynn JJ; Huang CC; Tseng LM
Front Oncol; 2023; 13():1192946. PubMed ID: 37655108
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PIK3CA mutations in breast cancer subtypes.
Arsenic R; Lehmann A; Budczies J; Koch I; Prinzler J; Kleine-Tebbe A; Schewe C; Loibl S; Dietel M; Denkert C
Appl Immunohistochem Mol Morphol; 2014 Jan; 22(1):50-6. PubMed ID: 24471188
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
7. Helical and kinase domain mutations of
Vatte C; Al Amri AM; Cyrus C; Chathoth S; Alsayyah A; Ahmad A; Akhtar MS; Alrashidi NF; Jayaseeli N; Al Wadani H; Al Zahrani A; Al Ali AK
Oncol Lett; 2019 Sep; 18(3):2427-2433. PubMed ID: 31404155
[TBL] [Abstract][Full Text] [Related]
8. [
Wu JH; Tian W; Tian GL; Tian MM; Chen SL; Tian W
Zhonghua Wai Ke Za Zhi; 2018 Jul; 56(7):538-542. PubMed ID: 30032537
[No Abstract] [Full Text] [Related]
9. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
[TBL] [Abstract][Full Text] [Related]
10. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in breast cancer: A Tunisian series.
Ben Rekaya M; Sassi F; Saied E; Bel Haj Kacem L; Mansouri N; Zarrouk S; Azouz S; Rammeh S
PLoS One; 2023; 18(5):e0285413. PubMed ID: 37195967
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.
Cheng J; Fu S; Wei C; Tania M; Khan MA; Imani S; Zhou B; Chen H; Xiao X; Wu J; Fu J
Cancer Biomark; 2017; 19(1):85-92. PubMed ID: 28269754
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
15. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
16. [PIK3CA gene mutations in Chinese women with HR
Wu SF; Wang XF; Liu YY; Xia C; Liang ZY; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1246-1250. PubMed ID: 36480834
[No Abstract] [Full Text] [Related]
17. [Correlation between the incidence of PIK3CA mutations in breast cancer and histopathological characteristics of the tumor].
Mendelová A; Jezková E; Zubor P; Holubeková V; Lasabová Z; Plank L; Danko J
Ceska Gynekol; 2014 Aug; 79(4):283-8. PubMed ID: 25398149
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
19. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of
Peixoto A; Cirnes L; Carvalho AL; Andrade MJ; Brito MJ; Borralho P; Coimbra N; Borralho PM; Carneiro AS; Castro L; Correia L; Dionísio MR; Faria C; Figueiredo P; Gomes A; Paixão J; Pinheiro M; Prazeres H; Ribeiro J; Salgueiro N; Schmitt FC; Silva F; Silvestre AR; Sousa AC; Almeida-Tavares J; Teixeira MR; André S; Machado JC
Front Mol Biosci; 2023; 10():1082915. PubMed ID: 36825198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
